Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1862 results
March 2015
-
Story From Our Labs
Vision hacker
Making clinical tools from basic research knowledge is a practice Novartis and FMI researchers pursue. Read how they want to help retinitis pigmentosa patients to see the light.
-
Story Discovery
Let there be sight
-
Press Release
FDA approves first biosimilar ZarxioTM (filgrastim-sndz) from Sandoz
Sandoz is the first company to receive approval of a biosimilar in the US through the new FDA biosimilars pathway established under BPCIA Zarxio is approved for all indications included in the… -
Press Release
Novartis announces completion of transactions with GSK
Completes transactions with GSK including: acquisition of GSK oncology portfolio, creation of Consumer Healthcare joint venture, and sale of non-influenza Vaccines business Sharpens company focus… -
Press Release
Novartis gibt Abschluss von Transaktionen mit GSK bekannt
Mit GSK abgeschlossene Transaktionen: Übernahme des Onkologie-Portfolios von GSK, Schaffung eines Joint Venture für Consumer Healthcare und Veräusserung des Bereichs Vaccines (ohne Grippeimpfstoffe… -
Press Release
Novartis annonce la conclusion des transactions avec GSK
Conclusion des transactions avec GSK incluant : l'acquisition du portefeuille oncologie de GSK, la création d'une coentreprise de Consumer Healthcare et la cession de l'activité vaccins (hors…
February 2015
-
Press Release
Positive phase II data highlights benefits of Alcon's RTH258 for patients with neovascular (wet) age-related macular degeneration
Phase II study met primary endpoint, demonstrating promising visual acuity gains in patients with neovascular (wet) age-related macular degeneration Data shows the potential for less… -
Press Release
Novartis shareholders approve all resolutions proposed by Novartis Board of Directors
Shareholders approve 18th consecutive dividend increase to CHF 2.60 (+6%) per share for 2014 Dr. Joerg Reinhardt confirmed by shareholders as Chairman of the Novartis Board of Directors as well… -
Press Release
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d'administration
Les actionnaires approuvent la 18e hausse consécutive du dividende, à CHF 2,60 par action (+6 %) au titre de l'exercice 2014. De même que d'autres administrateurs qui étaient candidats à leur… -
Press Release
Aktionäre genehmigen alle Anträge des Verwaltungsrats von Novartis
Aktionäre genehmigen für 2014 die 18. Dividendenerhöhung in Folge auf CHF 2,60 pro Aktie (+6%) Dr. Jörg Reinhardt als Präsident des Novartis Verwaltungsrats sowie alle weiteren Mitglieder des… -
Press Release
Novartis lung cancer drug Zykadia® recommended for EU approval in patients with ALK+ NSCLC previously treated with crizotinib
If approved, Zykadia (ceritinib) would be the first treatment option for patients in Europe with ALK+ NSCLC previously treated with crizotinib ALK+ NSCLC is driven by a rearrangement of the… -
Story Patient Perspectives
Why research into rare diseases matters
Hundreds of millions of people worldwide await treatments for rare diseases.